UCB (OTCMKTS:UCBJF) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $251.34, but opened at $235.10. UCB shares last traded at $235.10, with a volume of 1 shares traded.

Analyst Ratings Changes

UCBJF has been the subject of a number of research reports. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

UCB Trading Down 6.3%

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a 50 day moving average of $270.79 and a two-hundred day moving average of $288.60.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.